In a report released on February 7, Andrew Fein from H.C. Wainwright maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report), with a price target of $75.00. The company’s ...

Shares of CRBP opened at $8.78 on Friday. The firm has a market cap of $106.94 million, a PE ratio of -1.87 and a beta of 2.63. Corbus Pharmaceuticals has a 12 month low of $8.74 and a 12 month ...

Find the latest Corbus Pharmaceuticals Holdings CRBP analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.

1 Day CRBP -2.32% DJIA -0.07% Russell 2K 0.00% Health Care/Life Sciences -0.02% ...

Piper Sandler analyst Biren Amin maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today and set a price target of $35.00. The company’s shares closed yesterday at $9.90.

Shares of CRBP stock opened at $9.78 on Monday. The company’s fifty day simple moving average is $12.65 and its two-hundred day simple moving average is $27.00. Corbus Pharmaceuticals has a 52 ...

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) stock has reached a 52-week low, dipping to $10.43. With a beta of 2.64 and a trading range of $7.49 to $61.90 over the past... ByInvesting.com ...

(RTTNews) - Corbus Pharmaceuticals Holdings, Inc. (CRBP) announced on Tuesday that it will present updated data from its Phase 1 dose escalation study of CRB-701 or SYS6002 at the 2025 American ...

1 Day CRBP -1.11% DJIA -0.75% Russell 2K -0.86% Health Care/Life Sciences 0.29% ...